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Introduction
Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune disorders characterized by proximal muscle weakness and elevated creatine kinase (CK) levels [1] . It has been proposed that patients with specific serum autoantibodies exhibit characteristic clinical features and can be regarded as distinct clinical subsets [2] . Recent studies have found that the prevalence of anti-mitochondrial antibodies (AMAs) in IIMs varied markedly from 0. 6% to 19.5% and these AMA-positive IIM patients generally showed several unique characteristics [3] [4] [5] [6] [7] .
AMAs are biomarkers of primary biliary cirrhosis (PBC). Although IIMs with AMAs
were reported by Sherlock in 1973 [8] , large-scale studies have not been carried out until recent years. In Japan, Shimizu and colleagues demonstrated that patients with AMAs have a chronic disease course, muscle atrophy, cardiopulmonary involvement and granulomatous inflammation. These conclusions were partly confirmed by Christopher-Stine who revealed that AMA-associated IIMs frequently have chronic skeletal muscle disease and cardiac involvement and can occur in various subgroups. did not seem to be associated with cardiac involvement, muscular atrophy or a particular pathological feature in a European cohort as reported by Benveniste [3] [4] [5] [6] .
To date, no study has evaluated the prevalence, clinical features and treatment outcomes of AMA-associated IIMs in a Chinese patient cohort. Thus, we explored the prevalence of AMAs among 136 IIM patients and summarized the clinical, serological, histopathological characteristics and treatment outcomes of 7 AMA-positive patients.
Materials and Methods

Participants
Clinical data and serum samples were collected from 136 patients with IIM in the 
Clinical assessment
"Chronic disease duration" was defined as a duration from disease onset to first A C C E P T E D M A N U S C R I P T 7 examination over 12 months [10, 11] . Muscle strength was evaluated by the ordinal six-point 0-5 of manual muscle testing (MMT), and severe weakness was defined as no more than grade 3 in the weakest muscle [12] . PBC was diagnosed according to the criteria proposed by the American Association for the Study of Liver Disease [13] .
Detection of myositis-specific antibodies (MSAs), myositis-associated autoantibodies (MAAs) and AMAs
Patient serum was stored at -80°C. MSAs including anti-signal recognition particle 
Muscle biopsy
Muscle biopsies were performed before corticosteroid treatment. Serial frozen sections were stained with hematoxylin and eosin (HE), modified Gomori trichrome 
Treatment outcome measures
According to the definition of improvement made by the International Myositis Assessment and Clinical Studies Group, improvement was defined as three of any six
core set measures improved ≥ 20%, with no more than two measures worsening by ≥ 25% (which cannot be MMT) [15, 16] . Treatment outcomes were graded as no improvement, mild improvement (1 grade in at least one muscle group, persistently requiring assistance in daily activities), moderate improvement (>1 grade in multiple muscle groups, occasionally requiring assistance in daily activities), marked improvement (only mild weakness without functional impairment), and return to baseline (no symptoms or signs of muscle weakness) [17] . A favorable outcome was defined as marked improvement or return to baseline [17] .
Statistical analysis
Categorical variables were analyzed by Fisher's exact test as a predicted frequency < 5 and the significant p level was corrected by the Bonferroni method since multiple comparisons were made. The calculations were performed using the SPSS 20.0 statistical analysis software.
Results
Frequency of AMAs in IIM patients
AMAs were detected in 7 (5.15%) out of 136 IIM patients by line immunoassay. 
Clinical features
The clinical features of the 7 patients with AMA are summarized in Table 1 . There were 3 males and 4 females with ages at onset ranging from 41 to 70 years (mean ± SD, 54.71 ± 8.73 years). The duration from disease onset to the first visit varied from 1 to 24 months (mean ± SD, 8.58 ± 9.71 months) and chronic disease duration occurred in 2 patients without PBC. Indeed, asymmetrical limb weakness, which is infrequent in IIM, was seen in 4 patients including one with PBC. In addition, four patients experienced neck weakness, and 4 patients had distal muscle weakness.
Severe limbs weakness was observed in 4 patients, and muscle atrophy was found in 3 patients. Dysphagia was seen in 5 patients, dysarthria in three patients, myalgia in four patients and dyspnea in one patient who needed ventilatory support.
With regard to extramuscular manifestations, a periorbital heliotrope rash was found in all three DM patients. Cardiac muscle involvement was seen in two cases (one with PBC), including one with atrial premature beat and the other with complete right bundle branch block. One patient had a suspected malignancy as positron emission computed tomography revealed that fluorodeoxyglucose was highly absorbed by multiple lymph nodes in the right axillary area and under the chest muscle of the right anterior chest wall; however, this patient declined to undergo a biopsy. Furthermore, two patients had hepatic hemangioma (one of them was associated with PBC). No
rheumatic disease was found in these 7 patients. (Fig 1) .
Laboratory results
Serum
Histopathological findings of muscle biopsies
The seven patients with AMA were classified as 3 DM, 2 PM and 2 NAM (Fig 2) .
Considering that of the 129 AMA-negative patients, 70 were diagnosed as DM, 24 as PM, 17 as NSM and 18 as NAM, AMAs were not associated with a specific subgroup (p = 0.386). Cytoplasmic body and intermyofibrill network disorder in non-necrotic fibers were found in Patient 5. Sarcoplasmic mass and lobulated fibers were shown in Patient 4 (Fig 3) . Deposition of MAC was found in the sarcolemma of non-necrotic ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T 12 muscle fibers in 1 patient (without PBC) and in the capillaries in 4 patients (one patient with PBC and three patients without PBC). MHC-II was diffusely expressed in the sarcolemma of muscle fibers in 5 patients (two patients with PBC) and focally expressed in 1 patient (without PBC) (Fig 4) .
Treatment and outcomes
The detailed drug therapy and treatment outcomes of the 7 AMA-positive patients are summarized in Table 2 . All patients were initially treated with oral prednisone (1 mg/kg/day), and three required additional immunotherapies. Specifically, one was patients were drug free (one with PBC). CK levels declined to less than 400 U/L in all 6 patients and to normality in two patients (both without PBC). AMAs detected by both line immunoassay and IIF were still present after successful treatment in 4 of 5 patients.
A C C E P T E D M A N U S C R I P T 13
To further explore the characteristics of AMA-associated IIMs, we summarized the clinical features of our patients and previously reported patients in Table 3 . There was considerable variability in the prevalence of AMAs among patients with IIM and in the clinical and pathological features of these AMA-positive patients.
Discussion
This is the first study to evaluate the prevalence of AMAs in a large sample of In our study, the prevalence of AMAs in IIM patients was 5.15%, which is similar to that reported in France (7.80%) but quite higher than that reported in America (0.6%) and lower than that reported in Japan (11.3%-19.5%) [3] [4] [5] [6] . Although the Bohan and Peter inclusion criteria of low specificity used in the American research may partly explain the reason for our relatively higher AMA prevalence than that in America, there is still conspicuous heterogeneity in the prevalence of AMAs [19] .
Indeed, we found that the clinical features in patients with AMAs showed great variability. Firstly, although AMAs only occurred in adult IIM patients, the age at onset ranged from 23 years to 86 years and the mean age at onset ranged from the fourth decade to the seventh decade [3-5, 7, 8, 20-26] . Besides, the average disease duration varied from 10 months (in our study) to 6.5 years, and the prevalence of chronic disease duration varied from approximately 30% (in our study) to 85% [3, 5, 6] . In fact, although AMAs are regarded as the serological hallmarks of PBC, they are not always associated with PBC in IIM patients. Specifically, the frequency of PBC ranged largely from 15-75% [3] [4] [5] [6] . The frequency of cardiac involvement is relatively higher in AMA-associated IIM [3, 5, 6, 11, 17, 27] . This may be partly due to the presence of PBC because it is associated with increased cardiovascular disease risk [3, [28] [29] [30] . Thus, patients with AMAs should be followed up carefully for cardiac complications. In fact, the frequency of cardiac involvement also had a certain ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T 15 variability, ranging from approximately 30% to 70% [3] [4] [5] [6] . Furthermore, dysphagia, muscle atrophy, skin rash and restrictive ventilatory impairment also varied markedly in AMA-positive patients [3] [4] [5] [6] . Indeed, lung involvement was not easy to evaluate as it was not clearly and consistently defined. Specifically, some have reported the frequency of interstitial lung disease and others have studied the frequency of restrictive ventilatory impairment [3] [4] [5] [6] . In our cases, other autoimmune diseases such as systemic sclerosis, systemic lupus erythematosus or rheumatoid arthritis were not found, though they have been described in patients with AMAs and may even account Indeed, several unique clinical features which are similar to those seen in MD, such as chronic progression and asymmetrical muscle weakness, were not uncommon in AMA-positive IIM patients both in our study and in previous reports [3, 5, 6] . Other unique clinical characteristics that are rarely seen in IIM such as scapular winging and axial muscle involvement including lordotic posture, though not found in our patients, have been reported in previous studies [3] [4] [5] [6] . Since these features often occur in MD, Pompe or other muscle diseases in which AMAs have not yet been described, AMA testing could be considerably useful in the differential diagnosis between atypical IIM and other muscle diseases. Besides, hepatic hemangioma that has never been described in AMA-positive IIM patients was found in two of our patients. Whether With regard to the laboratory examinations of patients with AMAs, the mean CK level was about 2000U/L both in our study and in previous reports [3] [4] [5] [6] . The positive rate of many types of MSA were relatively low, despite the testing panels of MSA being different from those used in previous reports [3] [4] [5] . In fact, all 4 AMA-associated non-DM-IIM patients in our study did not have positivity for any [3, 4, 6] . However, the titer of AMA did not decrease in a majority of the patients after successful treatment, which may be partly due to the nature of AMAs [3] . Indeed, AMA titers do not change over time and are not correlated with disease activity or progression in PBC patients either [3, 37, 38] . Therefore, it is not advisable to use AMAs to modulate disease activity. As the treatment and outcomes were not comprehensively analyzed in previous studies, more studies are needed to confirm our findings.
We are aware of several limitations of the present study. Firstly, the number of patients with AMAs is small, thus the clinical features and treatment outcomes of AMA-positive patients need to be confirmed in further studies, especially in comparative studies. Secondly, some serum samples used for detecting AMAs were obtained during treatment or post-treatment, which limits the accuracy of the prevalence of AMAs. Nevertheless, this is a minor restriction since AMAs did not become negative after treatment in the majority of patients with our testing methods.
Thirdly, the exact prevalence of AMAs in IIM was uncertain as the comparison of the sensitivity and specificity between our two testing methods was not reported.
However, this is also a minor limitation because our two methods showed consistent results in most samples and the features of AMA-associated IIM that various clinical manifestations and favorable treatment outcomes were unchanged regardless of the A C C E P T E D M A N U S C R I P T 18 detection methods. Indeed, AMAs might need to be tested in multiple methods to obtain a comprehensive result, and the optimal method for detecting AMAs needs to be explored.
Conclusions
AMAs are relatively rare in Chinese patients with IIM. These AMA-positive patients generally show various clinical and histopathological features and favorable treatment outcomes. In addition, we suggest that AMA testing be performed to aid in the diagnosis of IIM, especially in patients with atypical IIM manifestations. Given that our present study is a retrospective review of a relatively small number of AMA-associated IIM patients, future studies involving a large cohort of patients are necessary to support our conclusions.
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